Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020206080 - CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS

Publication Number WO/2020/206080
Publication Date 08.10.2020
International Application No. PCT/US2020/026331
International Filing Date 02.04.2020
IPC
A61P 11/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
C07D 239/69 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
69Benzenesulfonamido-pyrimidines
C07D 515/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
515Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/241
02in which the condensed system contains two hetero rings
08Bridged systems
CPC
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
C07D 239/69
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
69Benzenesulfonamido-pyrimidines
C07D 515/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
515Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
02in which the condensed system contains two hetero rings
08Bridged systems
Applicants
  • VERTEX PHARMACEUTICALS INCORPORATED [US]/[US]
Inventors
  • ABELA, Alexander Russell
  • ABRAHAM, Sunny
  • ANDERSON, Corey Don
  • ARUMUGAM, Vijayalaksmi
  • CHAU, Jaclyn
  • CLEMENS, Jeremy
  • CLEVELAND, Thomas
  • DWIGHT, Timothy A.
  • FRIEMAN, Bryan A.
  • GROOTENHUIS, Peter (deceased)
  • HADIDA RUAH, Sara Sabina
  • ISHIHARA, Yoshihiro
  • KRENITSKY, Paul
  • MCCARTNEY, Jason
  • MELILLO, Vito
  • MILLER, Mark Thomas
  • SILINA, Alina
  • UY, Johnny
  • ZHOU, Jinglan
Agents
  • MCDONELL, Leslie A.
  • LEE, Eric J.
Priority Data
62/828,69903.04.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS
(FR) AGENTS DE MODULATION DE RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE FIBROSE KYSTIQUE
Abstract
(EN)
Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.
(FR)
L'invention concerne un composé (I), des dérivés deutérés et des sels pharmaceutiquement acceptables de l'un quelconque de ceux-ci. L'invention concerne également des procédés de traitement de la fibrose kystique à l'aide de ces composés.
Latest bibliographic data on file with the International Bureau